keyword
MENU ▼
Read by QxMD icon Read
search

William Chey

keyword
https://www.readbyqxmd.com/read/29764234/the-role-of-diet-in-the-management-of-irritable-bowel-syndrome-a-focus-on-fodmaps
#1
Russell Dolan, William D Chey, Shanti Eswaran
Irritable bowel syndrome is a common condition that negatively impacts quality of life and results in significant health care expenditures. The vast majority of IBS patients associate their symptoms with eating. Numerous randomized, controlled trials suggest that restriction of dietary FODMAPs improves overall symptoms, abdominal pain, bloating and quality of life in more than half of IBS sufferers. There is emerging data which suggests that other diets (gluten free, guided elimination diets) might also be of benefit to IBS patients...
May 15, 2018: Expert Review of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/29708822/rifaximin-is-associated-with-modest-transient-decreases-in-multiple-taxa-in-the-gut-microbiota-of-patients-with-diarrhoea-predominant-irritable-bowel-syndrome
#2
Anthony A Fodor, Mark Pimentel, William D Chey, Anthony Lembo, Pamela L Golden, Robert J Israel, Ian M Carroll
Rifaximin, a non-systemic antibiotic, is efficacious for the treatment of diarrhoea-predominant irritable bowel syndrome (IBS-D). Given the emerging association between the gut microbiota and IBS, this study examined potential effects of rifaximin on the gastrointestinal microbial community in patients with IBS-D. TARGET 3 was a randomised, double-blind, placebo-controlled, phase 3 study. Patients with IBS-D initially received open-label rifaximin 550 mg 3 times daily (TID) for 2 weeks. Patients who responded to the initial treatment and then relapsed were randomised to receive 2 repeat courses of rifaximin 550 mg TID or placebo for 2 weeks, with each course separated by 10 weeks...
April 30, 2018: Gut Microbes
https://www.readbyqxmd.com/read/29605985/lower-and-upper-gastrointestinal-symptoms-differ-between-individuals-with-irritable-bowel-syndrome-with-constipation-or-chronic-idiopathic-constipation
#3
Eric D Shah, Christopher V Almario, Brennan M R Spiegel, William D Chey
Background/Aims: We evaluated the distribution of lower and upper gastrointestinal (GI) symptoms among individuals with irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) in a nationwide survey. Methods: Individuals (≥ 18 years of age) were identified from a nationwide sample of > 70 000 United States adults. Participants completed the National Institutes of Health GI Patient Reported Outcomes Measurement Information System (NIH GI-PROMIS) questionnaire...
April 30, 2018: Journal of Neurogastroenterology and Motility
https://www.readbyqxmd.com/read/29509054/electronic-patient-agenda-forms-comparing-agreement-between-the-reason-for-specialty-consultation-reported-by-referring-providers-and-patients
#4
Shahzad Ahmed, Christopher V Almario, William D Chey, Lori A Robbins, Bianca Chang, Joseph Ahn, Jeffrey Ko, Phillip Gu, Alvin Siu, Brennan M R Spiegel
OBJECTIVE: Little is known about the agreement between referring providers' reason for specialty evaluation and patients' understanding of why they are referred for consultation. Here, we compared the reason for consult (RFC) documented by referring providers during usual care vs. the perceived RFC independently reported by patients through an e-portal just prior to the specialist visit. METHODS: We performed an observational study among patients referred for gastrointestinal (GI) evaluation...
March 6, 2018: Informatics for Health & Social Care
https://www.readbyqxmd.com/read/29408460/prevalence-of-and-factors-associated-with-fecal-incontinence-results-from-a-population-based-survey
#5
Stacy B Menees, Christopher V Almario, Brennan M R Spiegel, William D Chey
BACKGROUND & AIMS: Fecal incontinence (FI) is characterized by uncontrolled passage of solid or liquid stool. We aimed to determine the prevalence and severity of FI in a large sample of US residents. METHODS: We recruited a representative sample of patients in October 2015 to complete the National Gastrointestinal (GI) Survey; a mobile app called MyGiHealth was used to systematically collect data on GI symptoms. FI was defined as accidental leakage of solid or liquid stool...
May 2018: Gastroenterology
https://www.readbyqxmd.com/read/29408290/increased-prevalence-of-rare-sucrase-isomaltase-si-pathogenic-variants-in-irritable-bowel-syndrome-patients
#6
Koldo Garcia-Etxebarria, Tenghao Zheng, Ferdinando Bonfiglio, Luis Bujanda, Aldona Dlugosz, Greger Lindberg, Peter T Schmidt, Pontus Karling, Bodil Ohlsson, Magnus Simren, Susanna Walter, Gerardo Nardone, Rosario Cuomo, Paolo Usai-Satta, Francesca Galeazzi, Matteo Neri, Piero Portincasa, Massimo Bellini, Giovanni Barbara, Daisy Jonkers, Shanti Eswaran, William D Chey, Purna Kashyap, Lin Chang, Emeran A Mayer, Mira M Wouters, Guy Boeckxstaens, Michael Camilleri, Andre Franke, Mauro D'Amato
No abstract text is available yet for this article.
February 20, 2018: Clinical Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/29311737/response-to-hsu-et-al
#7
William D Chey, Grigorios I Leontiadis, Colin W Howden, Steven F Moss
No abstract text is available yet for this article.
January 2018: American Journal of Gastroenterology
https://www.readbyqxmd.com/read/29239347/chronic-constipation
#8
REVIEW
Michael Camilleri, Alexander C Ford, Gary M Mawe, Phil G Dinning, Satish S Rao, William D Chey, Magnus Simrén, Anthony Lembo, Tonia M Young-Fadok, Lin Chang
Chronic constipation is a prevalent condition that severely impacts the quality of life of those affected. Several types of primary chronic constipation, which show substantial overlap, have been described, including normal-transit constipation, rectal evacuation disorders and slow-transit constipation. Diagnosis of primary chronic constipation involves a multistep process initiated by the exclusion of 'alarm' features (for example, unintentional weight loss or rectal bleeding) that might indicate organic diseases (such as polyps or tumours) and a therapeutic trial with first-line treatments such as dietary changes, lifestyle modifications and over-the-counter laxatives...
December 14, 2017: Nature Reviews. Disease Primers
https://www.readbyqxmd.com/read/29156449/nutrition-in-the-management-of-gastrointestinal-diseases-and-disorders-the-evidence-for-the-low-fodmap-diet
#9
REVIEW
Shanti Eswaran, Jeremy P Farida, Jessica Green, Jesse D Miller, William D Chey
A growing interest from both physicians and patients is fueling research in the interaction of symptoms related to irritable bowel syndrome (IBS) and diet, particularly the low FODMAP diet. Recent studies further define the role of these short-chain fermentable carbohydrates on IBS symptoms and their effects in different parts of the gastrointestinal tract. Mounting evidence supports the use of a low FODMAP diet in the clinical setting, but this dietary approach is not without potential drawbacks. This review illustrates the mechanisms by which the low FODMAP diet leads to improvement in IBS symptoms, summarizes the available clinical evidence, and offers practical advice regarding implementation of this dietary strategy...
December 2017: Current Opinion in Pharmacology
https://www.readbyqxmd.com/read/29091082/low-dose-linaclotide-72-%C3%AE-g-for-chronic-idiopathic-constipation-a-12-week-randomized-double-blind-placebo-controlled-trial
#10
Philip Schoenfeld, Brian E Lacy, William D Chey, Anthony J Lembo, Caroline B Kurtz, David S Reasner, Wieslaw Bochenek, Kenneth Tripp, Mark G Currie, Susan M Fox, Rick E Blakesley, Christopher R O'Dea, Nicholas D Omniewski, Michael L Hall
OBJECTIVES: Linaclotide is a guanylate cyclase-C agonist approved in the United States, Canada, and Mexico at a once-daily 145-μg dose for the treatment of chronic idiopathic constipation (CIC); a once-daily 72-μg dose for CIC recently received FDA approval. The trial objective was to evaluate the efficacy and safety of a 72-μg linaclotide dose in CIC patients. METHODS: This double-blind, placebo-controlled trial randomized patients with CIC (Rome III criteria) to once-daily linaclotide 72 μg or 145 μg, or placebo for 12 weeks...
January 2018: American Journal of Gastroenterology
https://www.readbyqxmd.com/read/28881187/an-atypical-coincidence-of-colon-ischemia-and-bilateral-distal-ureteral-strictures
#11
Tossapol Kerdsirichairat, Eun-Young K Choi, William D Chey
No abstract text is available yet for this article.
September 4, 2017: Gastroenterology
https://www.readbyqxmd.com/read/28729815/symposium-report-an-evidence-based-approach-to-ibs-and-cic-applying-new-advances-to-daily-practice-a-review-of-an-adjunct-clinical-symposium-of-the-american-college-of-gastroenterology-meeting-october-16-2016-%C3%A2-las-vegas-nevada
#12
William D Chey
Many nonpharmacologic and pharmacologic therapies are available to manage irritable bowel syndrome (IBS) and chronic idiopathic constipation (CIC). The American College of Gastroenterology (ACG) regularly publishes reviews on IBS and CIC therapies. The most recent of these reviews was published by the ACG Task Force on the Management of Functional Bowel Disorders in 2014. The key objective of this review was to evaluate the efficacy of therapies for IBS or CIC compared with placebo or no treatment in randomized controlled trials...
February 2017: Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/28725080/response-to-georgopoulos-et-al
#13
William D Chey, Grigorios I Leontiadis, Colin W Howden, Steven F Moss
No abstract text is available yet for this article.
July 2017: American Journal of Gastroenterology
https://www.readbyqxmd.com/read/28710145/a-systematic-review-of-the-effects-of-polyols-on-gastrointestinal-health-and-irritable-bowel-syndrome
#14
REVIEW
Adrienne Lenhart, William D Chey
Polyols are sugar alcohols found in certain fruits, vegetables, and sugar-free sweeteners. They make up a component of the diet low in fermentable oligosaccharides, disaccharides, monosaccharides, and polyols, which is gaining popularity in the treatment of patients with irritable bowel syndrome (IBS). We conducted a systematic review to evaluate the effects of polyols on the gastrointestinal tract in healthy men and women and in patients with IBS. Utilizing PubMed, Ovid, and Embase databases, we conducted a search on individual polyols and each of these terms: fermentation, absorption, motility, permeability, and gastrointestinal symptoms...
July 2017: Advances in Nutrition
https://www.readbyqxmd.com/read/28706573/the-effects-of-catchment-and-riparian-forest-quality-on-stream-environmental-conditions-across-a-tropical-rainforest-and-oil-palm-landscape-in-malaysian-borneo
#15
Sarah H Luke, Holly Barclay, Kawi Bidin, Vun Khen Chey, Robert M Ewers, William A Foster, Anand Nainar, Marion Pfeifer, Glen Reynolds, Edgar C Turner, Rory P D Walsh, David C Aldridge
Freshwaters provide valuable habitat and important ecosystem services but are threatened worldwide by habitat loss and degradation. In Southeast Asia, rainforest streams are particularly threatened by logging and conversion to oil palm, but we lack information on the impacts of this on freshwater environmental conditions, and the relative importance of catchment versus riparian-scale disturbance. We studied 16 streams in Sabah, Borneo, including old-growth forest, logged forest, and oil palm sites. We assessed forest quality in riparian zones and across the whole catchment and compared it with stream environmental conditions including water quality, structural complexity, and organic inputs...
June 2017: Ecohydrology: Ecosystems, Land and Water Process Interactions, Ecohydrogeomorphology
https://www.readbyqxmd.com/read/28668539/a-diet-low-in-fermentable-oligo-di-and-monosaccharides-and-polyols-improves-quality-of-life-and-reduces-activity-impairment-in-patients-with-irritable-bowel-syndrome-and-diarrhea
#16
Shanti Eswaran, William D Chey, Kenya Jackson, Sivaram Pillai, Samuel W Chey, Theresa Han-Markey
BACKGROUND & AIMS: We investigated the effects of a diet low in fermentable oligo-, di-, and monosaccharides and polyols (FODMAPs) vs traditional dietary recommendations on health-related quality of life (QOL), anxiety and depression, work productivity, and sleep quality in patients with irritable bowel syndrome and diarrhea (IBS-D). METHODS: We conducted a prospective, single-center, single-blind trial of 92 adult patients with IBS-D (65 women; median age, 42...
December 2017: Clinical Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/28555632/corrigendum-eluxadoline-efficacy-in-ibs-d-patients-who-report-prior-loperamide-use
#17
Brian E Lacy, William D Chey, Brooks D Cash, Anthony J Lembo, Leonard S Dove, Paul S Covington
This corrects the article DOI: 10.1038/ajg.2017.72.
May 30, 2017: American Journal of Gastroenterology
https://www.readbyqxmd.com/read/28417992/eluxadoline-efficacy-in-ibs-d-patients-who-report-prior-loperamide-use
#18
RANDOMIZED CONTROLLED TRIAL
Brian E Lacy, William D Chey, Brooks D Cash, Anthony J Lembo, Leonard S Dove, Paul S Covington
OBJECTIVES: Irritable bowel syndrome with diarrhea (IBS-D) is often managed with over-the-counter therapies such as loperamide, though with limited success. This analysis evaluated the efficacy of eluxadoline in patients previously treated with loperamide in two phase 3 studies. METHODS: Adults with IBS-D (Rome III criteria) were enrolled and randomized to placebo or eluxadoline (75 or 100 mg) twice daily for 26 (IBS-3002) or 52 (IBS-3001) weeks. Patients reported loperamide use over the previous year and recorded their rescue loperamide use during the studies...
June 2017: American Journal of Gastroenterology
https://www.readbyqxmd.com/read/28244678/introduction
#19
William D Chey
No abstract text is available yet for this article.
March 2017: Journal of Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/28244495/tenapanor-treatment-of-patients-with-constipation-predominant-irritable-bowel-syndrome-a-phase-2-randomized-placebo-controlled-efficacy-and-safety-trial
#20
RANDOMIZED CONTROLLED TRIAL
William D Chey, Anthony J Lembo, David P Rosenbaum
OBJECTIVES: Tenapanor is a first-in-class, small-molecule inhibitor of the gastrointestinal sodium/hydrogen exchanger NHE3. This study assessed the efficacy and safety of tenapanor in patients with constipation-predominant irritable bowel syndrome (IBS-C). METHODS: In this phase 2, double-blind study, patients with IBS-C (Rome III criteria) were randomized (1:1:1:1) to receive tenapanor 5 mg, 20 mg, or 50 mg b.i.d., or placebo b.i.d. for 12 weeks. The primary end point was the complete spontaneous bowel movement (CSBM) responder rate, defined as the proportion of patients reporting an increase from baseline of ≥1 CSBM/week for ≥6/12 treatment weeks...
May 2017: American Journal of Gastroenterology
keyword
keyword
99798
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"